Top

Published in:

Open Access 01-12-2022 | Migraine | Research

The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients

Authors: Ruth Ruscheweyh, Theresa Klonowski, Gudrun Goßrau, Torsten Kraya, Charly Gaul, Andreas Straube, Tim Patrick Jürgens, Jörg Scheidt, Stefanie Förderreuther

Published in: The Journal of Headache and Pain | Issue 1/2022

Abstract

Background

Although good treatment options exist for many headache disorders, not all patients benefit and disability continues to be large. To design strategies for improving headache care, real-world data observing standard care is necessary. Therefore, the German Migraine and Headache Society (DMKG) has established the DMKG Headache Registry. Here we present methods and baseline data.

Methods

Accredited German headache centers (clinic-based or private practice) can offer participation to their patients. Patients provide headache history, current headache load (including a mobile headache diary), medication and comorbidities and answer validated questionnaires, prior to their physician appointment. Physicians use these data as the base of their history taking, and add, change or confirm some central information. Before the next visit, patients are asked to update their data. Patients will continuously be included over the next years.

Results

The present analysis is based on the first 1,351 patients (1110 females, 39.6 ± 12.9 years) with a completed first visit. Most participants had a migraine diagnosis. Participants had 14.4 ± 8.5 headache days and 7.7 ± 6.1 acute medication days per month and 63.9% had a migraine disability assessment (MIDAS) grade 4 (severe disability). 93.6% used at least one acute headache medication, most frequently a triptan (60.0%) or non-opioid analgesic (58.3%). 45.0% used at least one headache preventive medication, most frequently an antidepressant (11.4%, mostly amitriptyline 8.4%) or a CGRP(receptor) antibody (9.8%). Most common causes for discontinuation of preventive medication were lack of effect (54.2%) and side effects (43.3%).

Conclusion

The DMKG Headache Registry allows to continuously monitor headache care at German headache centers in both a cross-sectional and a longitudinal approach.

Trial registration

The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).

GBD (2016) Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459–480. https://doi.org/10.1016/S1474-4422(18)30499-XCrossRef

Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https://doi.org/10.1186/s10194-018-0955-yCrossRefPubMedPubMedCentral

Diener H-C, Holle-Lee D, Nägel S et al (2019) Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci 3:2514183X18823377CrossRef

Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021–1039. https://doi.org/10.1111/head.14153CrossRefPubMed

Katsarava Z, Mania M, Lampl C et al (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19:10. https://doi.org/10.1186/s10194-018-0839-1CrossRefPubMedPubMedCentral

Blumenfeld AM, Bloudek LM, Becker WJ et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53:644–655. https://doi.org/10.1111/head.12055CrossRefPubMed

Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia Int J Headache 37:470–485. https://doi.org/10.1177/0333102416678382CrossRef

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache 38:1–211. https://doi.org/10.1177/0333102417738202

(2020) Guideline on registry-based studies – Draft. https://www.ema.europa.eu/en/guideline-registry-based-studies (2020, accessed 23 Mar 2022).

10.

Gliklich RE, Leavy MB, Dreyer NA (2020) Registries for Evaluating Patient Outcomes: A User’s Guide. 4th ed. (Prepared by L&M Policy Research, LLC, under Contract No. 290-2014-00004-C with partners OM1 and IQVIA) AHRQ Publication No. 19(20)-EHC020. Rockville: Agency for Healthcare Research and Quality. Posted final reports are located on the Effective Health Care Program search page. https://doi.org/10.23970/AHRQEPCREGISTRIES4

11.

Stewart WF, Lipton RB, Whyte J et al (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988–994. https://doi.org/10.1212/wnl.53.5.988CrossRefPubMed

12.

Nilges P, Essau C (2015) Depression, anxiety and stress scales: DASS–A screening procedure not only for pain patients. Schmerz Berl Ger 29:649–657. https://doi.org/10.1007/s00482-015-0019-zCrossRef

13.

Lovibond SH, Lovibond PF (1996) Manual for the depression anxiety stress scales. Psychology Foundation of Australia, Sydney

14.

Kazis LE, Miller DR, Skinner KM et al (2004) Patient-reported measures of health: the Veterans health study. J Ambulatory Care Manage 27:70–83. https://doi.org/10.1097/00004479-200401000-00012CrossRefPubMed

15.

Hüppe M, Schneider K, Casser H-R et al (2022) Characteristic values and test statistical goodness of the Veterans RAND 12-Item Health Survey (VR-12) in patients with chronic pain : an evaluation based on the KEDOQ pain dataset. Schmerz Berl Ger 36:109–120. https://doi.org/10.1007/s00482-021-00570-5CrossRef

16.

Schwedt TJ, Digre K, Tepper SJ et al (2020) The American registry for migraine research: research methods and baseline data for an initial patient cohort. Headache 60:337–347. https://doi.org/10.1111/head.13688CrossRefPubMed

17.

Pearl TA, Dumkrieger G, Chong CD et al (2020) Sensory hypersensitivity symptoms in migraine with vs without aura: results from the American registry for migraine research. Headache 60:506–514. https://doi.org/10.1111/head.13745CrossRefPubMed

18.

Pearl TA, Dumkrieger G, Chong CD et al (2020) Impact of depression and anxiety symptoms on patient-reported outcomes in patients with migraine: results from the American Registry for Migraine Research (ARMR). Headache 60:1910–1919. https://doi.org/10.1111/head.13911CrossRefPubMed

19.

Trivedi M, Dumkrieger G, Chong CD et al (2021) Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research. Headache 61:740–754. https://doi.org/10.1111/head.14100CrossRefPubMed

20.

Peikert A, Koerwer M, Tozzi V, et al (2020) First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry (Abstract 1760). Neurology. 94(15 Supplement)

21.

Hornik CP, Gelfand AA, Szperka CL et al (2020) Development of a prospective real-world data clinical registry of children and adolescents with migraine. Headache 60:405–415. https://doi.org/10.1111/head.13714CrossRefPubMed

22.

Cho S-J, Lee MJ, Kim B-K, et al (2019) Clinical features of chronic cluster headache based on the third edition of the International Classification of Headache Disorders: a prospective multicentre study. PloS One. 14:e0221155. https://doi.org/10.1371/journal.pone.0221155

23.

Belvís R, Irimia P, Pozo-Rosich P et al (2021) MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain 22:74. https://doi.org/10.1186/s10194-021-01267-xCrossRefPubMedPubMedCentral

24.

Silberstein SD, Olesen J, Bousser M-G, et al (2005) The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache. Cephalalgia Int J Headache. 25:460–465. https://doi.org/10.1111/j.1468-2982.2005.00878.x

25.

Dresler T, Caratozzolo S, Guldolf K et al (2019) Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain 20:51. https://doi.org/10.1186/s10194-019-0988-xCrossRefPubMedPubMedCentral

26.

Le H, Tfelt-Hansen P, Russell MB et al (2011) Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia Int J Headache 31:43–64. https://doi.org/10.1177/0333102410373159CrossRef

27.

Dekker F, Dieleman JP, Neven AK et al (2013) Preventive treatment for migraine in primary care, a population-based study in the Netherlands. Cephalalgia Int J Headache 33:1170–1178. https://doi.org/10.1177/0333102413490343CrossRef

28.

Dekker F, Neven AK, Andriesse B et al (2012) Prophylactic treatment of migraine by GPs: a qualitative study. Br J Gen Pract J R Coll Gen Pract 62:e268-274. https://doi.org/10.3399/bjgp12X636100CrossRef

29.

Müller B, Dresler T, Gaul C et al (2020) Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. J Headache Pain 21:49. https://doi.org/10.1186/s10194-020-01099-1CrossRefPubMedPubMedCentral

30.

Steiner TJ, Jensen R, Katsarava Z et al (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20:57. https://doi.org/10.1186/s10194-018-0899-2CrossRefPubMedPubMedCentral

Title: The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
Authors: Ruth Ruscheweyh
Theresa Klonowski
Gudrun Goßrau
Torsten Kraya
Charly Gaul
Andreas Straube
Tim Patrick Jürgens
Jörg Scheidt
Stefanie Förderreuther
Publication date: 01-12-2022
Publisher: Springer Milan
Keywords: Migraine
Headache
Published in: The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-022-01447-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine

Imaging the inflammatory phenotype in migraine

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study

Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine